Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IAP0971 in Advanced Malignant Tumors
NCT05396391Phase 2Unknown
- Sponsor
- SUNHO BioPharmaceutical
- Start
- Jun 2022
- Primary completion
- May 2024
- Modality
- Immunomodulatory ADCs, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of IAP0971 in solid tumor (advanced stage), non-Hodgkin lymphoma (NHL), sponsored by SUNHO BioPharmaceutical. Status: unknown.
02
Drugs
IAP0971
03
Conditions
solid tumor (advanced stage)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05396391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05396391.